Serum endocannabinoid content is altered in females with depressive disorders: A preliminary report

Pharmacopsychiatry

Volumn 41, Issue 2, 2008, Pages 48-53

  Hill, M N ^a   Miller, G E ^a   Ho, W S V ^b   Gorzalka, B B ^a   Hillard, C J ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID;

ADULT; ANXIETY; ARTICLE; COGNITION; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROLOGY; SERUM; STATISTICAL SIGNIFICANCE; WOMEN'S HEALTH;

ADULT; ANXIETY; ARACHIDONIC ACIDS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HUMANS; MASS SPECTROMETRY; POLYUNSATURATED ALKAMIDES; PSYCHIATRIC STATUS RATING SCALES;

EID: 41149130214     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993211     Document Type: Article

References (40)

1. American Psychiatric Association. Diagnostic and Statistical manual of mental disorders 4th ed. Washington DC: American Psychiatric Association 1994
2. Barna I, Zelena D, Arszovszki AC, Ledent C. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. Life Sci 2004; 75: 2959-2970
3. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431
4. Freedland KE, Skala JA, Carney RM, Raczynski JM, Taylor CB, Mendes de Leon CF. The Depression Interview and Structured Hamilton (DISH): rationale, development, characteristics, and clinical validity. Psychosom Med 2002; 64: 897-905
5. Gaetani S, Cuomo V, Piomelli D. Anandamide hydrolysis: a new target for anti-anxiety drugs? Trends Mol Med 2003; 9: 474-478
6. Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004; 29: 2108-2114
7. Glaser ST, Gatley SJ, Gifford AN. Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain. J Pharmacol Exp Ther 2006; 316: 1088-1097
8. Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci USA 2005; 102: 18620-18625
9. Gonzalez S, Fernandez-Ruiz J, Di Marzo V, Hernandez M, Arevalo C, Nicanor C et al. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug Alcohol Depend 2004; 74: 159-170
10. Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 2005; 57: 261-267
11. Gruber AJ, Pope Jr HG, Brown ME. Do patients use marijuana as an antidepressant? Depression 1996; 4: 77-80
12. Hill MN, Gorzalka BB. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 2005; 15: 593-599
13. Hill MN, Gorzalka BB. Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression? Behav Pharmacol 2005; 16: 333-352
14. Hill MN, Patel S, Carrier EJ, Rademacher DJ, Ormerod BK, Hillard CJ et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 2005; 30: 508-515
15. Hill MN, Karacabeyli ES, Gorzalka BB. Estrogen recruits the endocannabinoid system to modulate emotionality. Psychoneuroendocrinology 2007; 32: 350-357
16. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur Psychiatry 2002; 17 (Suppl 3): 294-299
17. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 2000; 23: 477-501
18. Hungund BL, Vinod KY, Kassir SA, Basavarajappa BS, Yalamanchili R, Cooper TB et al. Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. Mol Psychiatry 2004; 9: 184-190
19. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81
20. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L et al. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74: 486-496
21. Kunos G, Jarai Z, Batkai S, Goparaju SK, Ishac EJ, Liu J et al. Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 2000; 108: 159-168
22. Leonard BE, Song C. Stress and the immune system in the etiology of anxiety and depression. Pharmacol Biochem Behav 1996; 54: 299-303
23. Lopez JF, Chalmers DT, Little KY, Watson SJ. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998; 43: 547-573
24. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-534
25. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 2002; 159: 379-387
26. MacPartland JM, Giuffrida A, King J, Skinner E, Scotter J, Musty RE. Cannabimimetic effects of osteopathic manipulative treatment. J Am Osteopath Assoc 2005; 105: 283-291
27. Maechoulam R, Fride E, Di Marzo V. Endocannabinoids. Eur J Pharmacol 1998; 359: 1-18
28. Patel S, Carrier EJ, Ho WS, Rademacher DJ, Cunningham S, Reddy DS et al. The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. J Lipid Res 2005; 46: 342-349
29. Patel S, Hillard CJ. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 2006; 318: 304-311
30. Radloff LS. The CES-D scale: A self-report depression scale for research in the general population. J App Psychol Meas 1977; 1: 385-401
31. Robins LN, Helzer JE, Croughan J, Ratcliff K. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Arch Gen Psychiatry 1981; 38: 381-389
32. Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology 2004; 176: 223-232
33. Shearman LP, Rosko KM, Fleischer R, Wang J, Xu S, Tong XS et al. Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice. Behav Pharmacol 2003; 14: 573-582
34. Song C, Horrobin DF, Leonard BE. The comparison of changes in behavior, neurochemistry, endocrine, and immune functions after different routes, doses and durations of administrations of IL-1beta in rats. Pharmacopsychiatry 2006; 39: 88-99
35. Spitzer RL, Williams JB, Kroenke K, Linzer M, deGruy FV, Hahn SR et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA 1994; 272: 1749-1756
36. Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP et al. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003; 138: 544-553
37. Vaidya VA, Duman RS. Depresssion emerging insights from neurobiology. Br Med Bull 2001; 57: 61-79
38. Williams JB. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 1988; 45: 742-747
39. Willoughby KA, Moore SF, Martin BR, Ellis EF. The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 1997; 282: 243-247
40. Yukimasa T, Yoshimura R, Tamagawa A, Uozumi T, Shinkai K, Ueda N et al. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 2006; 39: 52-59